Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
231.60
-3.72 (-1.58%)
May 14, 2026, 11:59 AM EDT - Market open
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $191.20M in the quarter ending March 31, 2026, with 57.42% growth. This brings the company's revenue in the last twelve months to $708.24M, up 63.88% year-over-year. In the year 2025, Axsome Therapeutics had annual revenue of $638.50M with 65.55% growth.
Revenue (ttm)
$708.24M
Revenue Growth
+63.88%
P/S Ratio
17.10
Revenue / Employee
$580,521
Employees
1,220
Market Cap
11.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 638.50M | 252.80M | 65.55% |
| Dec 31, 2024 | 385.69M | 115.09M | 42.53% |
| Dec 31, 2023 | 270.60M | 220.56M | 440.80% |
| Dec 31, 2022 | 50.04M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.44B |
| BioMarin Pharmaceutical | 3.24B |
| Exelixis | 2.38B |
| Madrigal Pharmaceuticals | 1.13B |
| Ionis Pharmaceuticals | 1.06B |
| Arrowhead Pharmaceuticals | 622.01M |
| BridgeBio Pharma | 579.96M |
| Krystal Biotech | 417.30M |
AXSM News
- 2 days ago - Axsome Therapeutics Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 7 days ago - Axsome Therapeutics Recognizes Mental Health Month - GlobeNewsWire
- 9 days ago - Axsome Therapeutics price target lowered to $280 from $281 at Deutsche Bank - TheFly
- 9 days ago - Axsome Therapeutics price target raised to $267 from $255 at Needham - TheFly
- 9 days ago - Axsome Therapeutics price target raised to $242 from $217 at Morgan Stanley - TheFly
- 9 days ago - Axsome Therapeutics price target raised to $302 from $242 at RBC Capital - TheFly
- 9 days ago - Axsome Therapeutics price target raised to $310 from $228 at Mizuho - TheFly
- 9 days ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire